Yuki Kagoya received his MD at the University of Tokyo in 2007 and completed clinical training for Internal Medicine, Hematology & Medical Oncology, and Transplantation Medicine. He was then involved in basic research on leukemia initiating cells during his PhD training. Through these experiences, Y. Kagoya recognized the power of immunological reactions against cancer cells and joined Dr. Naoto Hirano’s laboratory at Princess Margaret Cancer Centre, Toronto to be dedicated to research on cancer immunology and immunotherapy (2014-2018). He currently serves as Chief of Division of Immune Response at Aichi Cancer Center Research Institute (Nagoya, Japan). He is also affiliated as Adjunct Professor at Nagoya University Graduate School of Medicine. The research interest of Y. Kagoya is to develop effective, safe, and off-the-shelf cancer immunotherapy to cure patients with advanced cancer. In addition to basic research on elucidating T-cell immunity at molecular levels, He is also engaged in translational research to develop a novel antitumor immunotherapeutic, including adoptive immunotherapy using chimeric antigen receptor (CAR)-engineered T cells and tumor-infiltrating lymphocytes (TIL).